This bill, titled the "Freedom to Heal Act of 2025," amends the Controlled Substances Act to create a special registration process for physicians. This process specifically allows physicians to directly administer Schedule I eligible investigational drugs to patients who qualify under the federal Right to Try law. The primary goal is to enable patients with life-threatening conditions to access experimental treatments that are currently classified as Schedule I controlled substances, which typically have strict research limitations. To obtain this special registration, physicians must submit an application to the Attorney General, demonstrating compliance with the Right to Try law, including manufacturer documentation and an agreement to supply the drug. The application also requires evidence of the physician's qualifications, state law compliance, and a description of the storage and administration site. The Attorney General must approve or issue a show cause order within 45 days and is mandated to establish an interim final rule within 240 days to govern the delivery, storage, security, and record-keeping for these drugs, ensuring effective controls against diversion.